Shares of Trevi Therapeutics Inc (NASDAQ:TRVI) have received an average broker rating score of 1.25 (Strong Buy) from the four brokers that provide coverage for the stock, Zacks Investment Research reports. One analyst has rated the stock with a buy rating and three have assigned a strong buy rating to the company.

Brokers have set a 12 month consensus price objective of $16.75 for the company and are forecasting that the company will post ($0.63) earnings per share for the current quarter, according to Zacks. Zacks has also given Trevi Therapeutics an industry rank of 73 out of 256 based on the ratings given to related companies.

A number of research analysts recently issued reports on TRVI shares. Stifel Nicolaus started coverage on Trevi Therapeutics in a report on Monday, June 3rd. They issued a “buy” rating and a $20.00 price target for the company. Leerink Swann started coverage on Trevi Therapeutics in a report on Monday, June 3rd. They issued an “outperform” rating for the company. BMO Capital Markets started coverage on Trevi Therapeutics in a report on Monday, June 3rd. They issued an “outperform” rating and a $15.00 price target for the company. Needham & Company LLC assumed coverage on Trevi Therapeutics in a report on Monday, June 3rd. They issued a “buy” rating and a $18.00 price target for the company. Finally, Svb Leerink began coverage on Trevi Therapeutics in a research report on Monday, June 3rd. They set an “outperform” rating and a $14.00 target price for the company.

In other news, Director Anne Vanlent acquired 5,000 shares of the firm’s stock in a transaction on Thursday, May 9th. The shares were purchased at an average cost of $10.00 per share, with a total value of $50,000.00. The purchase was disclosed in a filing with the SEC, which is available through this link. Also, insider Jennifer L. Good acquired 11,250 shares of the firm’s stock in a transaction on Thursday, May 9th. The stock was purchased at an average cost of $10.00 per share, for a total transaction of $112,500.00. The disclosure for this purchase can be found here. Over the last ninety days, insiders acquired 391,250 shares of company stock worth $3,912,500.

Shares of NASDAQ TRVI opened at $7.95 on Monday. Trevi Therapeutics has a 52-week low of $7.18 and a 52-week high of $10.62.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. The company's nalbuphine ER, which is in Phase IIb/III clinical trial is an oral extended release formulation of nalbuphine that is used for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease.

Featured Story: Cost of Debt

Get a free copy of the Zacks research report on Trevi Therapeutics (TRVI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Trevi Therapeutics (NASDAQ:TRVI)

Receive News & Ratings for Trevi Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevi Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.